The Effect of Overencapsulation on Disintegration and Dissolution - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Effect of Overencapsulation on Disintegration and Dissolution
The authors examined the disintegration and dissolution profiles of propranolol and rofecoxib tablets overencapsulated with standard hard-gelatin capsules and with capsules specifically designed for double-blind clinical trials.


Pharmaceutical Technology
Volume 34, Issue 4, pp. 104-111

Materials and methods

Materials. Propranolol hydrochloride, US Pharmacopeia tablets (blue color), 20 mg, and rofecoxib (Vioxx) tablets (yellow color), 25 mg, were purchased from Pliva (East Hanover, NJ), and Merck & Co. (Whitehouse Station, NJ), respectively. DBcaps capsules (DBcaps Size B) and standard gelatin capsules (HGC size 00) were supplied by Capsugel (Peapack, NJ). Microcrystalline cellulose (Avicel PH102) was donated by FMC Biopolymer (Philadelphia), and Foremost Farms (Baraboo, WI) supplied anhydrous lactose. A Vankel dissolution apparatus and a Delphian fiber-optic dissolution-monitoring system from Delphian (Woburn, MA) were used.

Experimental design. Two blocks of 2 2 2 randomized full-factorial design were used to determine the effect of three independent parameters. Two levels (i.e., two drug types, propranolol and rofecoxib), two capsule types (i.e., DBcaps and HGC), and two filler levels (i.e., microcrystalline cellulose–lactose 1:1 mixture and no filler) were used in the design.

Capsule backfilling. A predetermined weight of a 1:1 physical mixture of anhydrous lactose:microcrystalline cellulose was filled into the capsule body. The tablet was placed on the backfill, and the capsule cap was snapped on to lock in place. When backfill was not required, only the tablet was filled into the capsule.

Weight variation. Twenty capsules from each batch were weighed, and the average weight, standard deviation, and percent relative standard deviation (RSD) were computed. To remove bias, the hand filling of the capsules was blinded from the analyst who conducted the weight-variation experiment. The samples were also coded.

Disintegration test. A Vankel disintegration apparatus, running at 30 dips per minute (dpm), and simulated gastric fluid (pH 1.2) without pepsin were used for the disintegration test. Two randomly selected capsules from a batch were tested at a time. This test was repeated three times, making a total of six capsules from each batch. The average disintegration (D-time) was computed. Two capsules were run at a time to allow a video camera (MDS 100, Kodak, Rochester, NY) to capture the process of capsule disintegration.

Dissolution analysis. The Vankel dissolution apparatus and Delphian RAINBOW dynamic dissolution-monitor system, consisting of six photodiode-array probes with a cell length of 10 mm, were used. Simulated gastric fluid (pH of 1.2) without pepsin, degassed at 40 C, was used as the medium at 37 C.

A spectrophotometric linearity test was performed to test each individual probe for linearity and reproducibility. Using the blank dissolution medium, the fiber-optic system first acquired the 100% transmittance. This step was followed by calibration, which involved collecting the transmittance from three replicates of six standard solutions. The percent difference and percent RSD were calculated, and the linearity was determined.

The dissolution of propranolol was determined using the USP Apparatus I (or basket method) at 50 rpm in 900 mL of simulated gastric fluid. A filtered solution of 20 mg of propranolol in 900 mL of simulated gastric fluid was used as the standard. Peak absorbance wavelength and baseline correction wavelength were 288 nm and 370 nm, respectively.

For rofecoxib, the USP Apparatus II (or paddle method) was used at 50 rpm in 900 mL of simulated gastric fluid. A filtered solution of 25 mg of rofecoxib in 900 mL of simulated gastric fluid was used as the standard. The peak absorbance wavelength and baseline correction wavelength were 268 nm and 370 nm, respectively. Replicates of eight batches were tested, making a total of 16 runs.

Statistical analysis. The f 2 similarity factor (see Eq. 1) was used to compare the dissolution profiles. Six and 16 time points were used for propranolol and rofecoxib, respectively, because of differences between the two drugs' dissolution rates. When comparing the dissolution profiles of encapsulated and unencapsulated tablets, the data were normalized for a lag time of 2 min (13). The significance of individual parameters' effects and their influence on disintegration time and dissolution were determined using a least-squares regression model (p-value < 0.05).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here